Clinical Trial Update: Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC [Phase 2]

View source ↗

Summary

Phase 2a trial evaluating high-dose testosterone prior to radioligand therapy in metastatic castration-resistant prostate cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Lutetium-177 PSMA-617 (lutetium Lu-177 PSMA-617)
• TESTOSTERONE (testosterone)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: RECRUITING